Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $77.70
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12-month target price among […]
More Stories
Silver Spruce Resources (CVE:SSE) Hits New 1-Year Low – Time to Sell?
Silver Spruce Resources Inc. (CVE:SSE – Get Free Report)’s stock price reached a new 52-week low on Monday . The...
International Lithium (CVE:ILC) Sets New 52-Week Low – Should You Sell?
International Lithium Corp. (CVE:ILC – Get Free Report) shares hit a new 52-week low during mid-day trading on Monday ....
OPG Power Ventures (LON:OPG) Stock Price Down 7.7% – Here’s What Happened
Shares of OPG Power Ventures Plc (LON:OPG – Get Free Report) dropped 7.7% on Wednesday . The stock traded as...
Serve Robotics (NASDAQ:SERV) Shares Down 4% – What’s Next?
Shares of Serve Robotics Inc. (NASDAQ:SERV – Get Free Report) dropped 4% during trading on Wednesday . The company traded...
Globalstar (GSAT) vs. Its Peers Head to Head Comparison
Profitability This table compares Globalstar and its peers’ net margins, return on equity and return on assets. Net Margins Return...
Macarthur Minerals (CVE:MMS) Reaches New 52-Week Low – Should You Sell?
Macarthur Minerals Limited (CVE:MMS – Get Free Report) reached a new 52-week low during trading on Monday . The stock...